Polymerase Inhibition by Nucleoside Analogs: Cellular- and Kinetic Parameters of Efficacy, Susceptibility and Resistance Selection by von Kleist, M. et al.
HIV-1 Polymerase Inhibition by Nucleoside Analogs:
Cellular- and Kinetic Parameters of Efficacy,
Susceptibility and Resistance Selection
Max von Kleist1*, Philipp Metzner2, Roland Marquet3, Christof Schu¨tte1
1Department of Mathematics and Computer Science, Free University Berlin, Berlin, Germany, 2 Institute of Computational Science, University of Lugano, Lugano,
Switzerland, 3Architecture et Re´activite´ de l’ARN, Universite´ de Strasbourg, CNRS, IBMC, Strasbourg, France
Abstract
Nucleoside analogs (NAs) are used to treat numerous viral infections and cancer. They compete with endogenous
nucleotides (dNTP/NTP) for incorporation into nascent DNA/RNA and inhibit replication by preventing subsequent primer
extension. To date, an integrated mathematical model that could allow the analysis of their mechanism of action, of the
various resistance mechanisms, and their effect on viral fitness is still lacking. We present the first mechanistic mathematical
model of polymerase inhibition by NAs that takes into account the reversibility of polymerase inhibition. Analytical solutions
for the model point out the cellular- and kinetic aspects of inhibition. Our model correctly predicts for HIV-1 that resistance
against nucleoside analog reverse transcriptase inhibitors (NRTIs) can be conferred by decreasing their incorporation rate,
increasing their excision rate, or decreasing their affinity for the polymerase enzyme. For all analyzed NRTIs and their
combinations, model-predicted macroscopic parameters (efficacy, fitness and toxicity) were consistent with observations.
NRTI efficacy was found to greatly vary between distinct target cells. Surprisingly, target cells with low dNTP/NTP levels may
not confer hyper-susceptibility to inhibition, whereas cells with high dNTP/NTP contents are likely to confer natural
resistance. Our model also allows quantification of the selective advantage of mutations by integrating their effects on viral
fitness and drug susceptibility. For zidovudine triphosphate (AZT-TP), we predict that this selective advantage, as well as the
minimal concentration required to select thymidine-associated mutations (TAMs) are highly cell-dependent. The developed
model allows studying various resistance mechanisms, inherent fitness effects, selection forces and epistasis based on
microscopic kinetic data. It can readily be embedded in extended models of the complete HIV-1 reverse transcription
process, or analogous processes in other viruses and help to guide drug development and improve our understanding of
the mechanisms of resistance development during treatment.
Citation: von Kleist M, Metzner P, Marquet R, Schu¨tte C (2012) HIV-1 Polymerase Inhibition by Nucleoside Analogs: Cellular- and Kinetic Parameters of Efficacy,
Susceptibility and Resistance Selection. PLoS Comput Biol 8(1): e1002359. doi:10.1371/journal.pcbi.1002359
Editor: Thomas Lengauer, Max-Planck-Institut fu¨r Informatik, Germany
Received August 1, 2011; Accepted December 5, 2011; Published January 19, 2012
Copyright: ß 2012 von Kleist et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: MvK acknowledges acknowledges financial support by the German Ministry of Education and Sciences (BMBF) and from the DFG research center
MATHEON. PM acknowledges funding from the DFG research center MATHEON and DFG SPP 1276 (MetStro¨m). RM was supported by grants from Sidaction and
ANRS (Agence Nationale de Recherches sur le SIDA et les He´patites). The funders had no role in study design, data collection and analysis, decision to publish, or
preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: vkleist@zedat.fu-berlin.de
Introduction
Viral encoded polymerases perform essential enzymatic steps
through amplification- or transformation of the viral genome
during the viral life cycle [1]. As such, viral encoded polymerases
constitute an attractive drug target for the treatment of many viral
infections [2]. Nucleoside analogs (NAs) were among the first
polymerase inhibitors that showed clinical efficacy [3–5] and are
nowadays broadly used to treat hepatitis B-, herpes simplex- and
HIV-1 infection [2], where they constitute the typical backbone
components of modern highly active antiretroviral treatment
(HAART). Nucleoside analogs are typically formulated as pro-
drugs, which require intracellular phosphorylation to form an
analog of (deoxy-) nucleoside-triphosphate (NA-TP; mimicking
either adenosine, thymidine, guanine, cytosine or uracil), which
can be incorporated into nascent viral DNA by the viral
polymerase. After incorporation, nucleoside analogs bring the
polymerization machinery to a halt, as they lack the chemical
group that is necessary to attach the next incoming nucleotide [6].
Incorporated NAs can, however, be selectively excised by some
viral polymerases, rescuing the nascent viral DNA and inducing a
transient-, rather than permanent mode of inhibition. Inhibition of
the crucial step of viral DNA polymerization can lower the
probability by which circulating virus can successfully infect host
cells [7] and the number of viral progeny produced per unit time,
shifting the balance between viral clearance by the immune system
and viral replication in favor of the immune system. For the ease of
notation, we will subsequently only refer to the active (tri-
phosphorylated) nucleoside analog moiety.
Inhibition of DNA polymerization by NAs is not restricted to
viral polymerase, but can also affect cellular polymerases, leading
to unwanted side-effects [8,9]. The therapeutic window of NAs
largely depends on molecular kinetic properties of the respective
enzymes with regard to a particular inhibitor [10,11]. NAs
therefore require high specificity for the targeted viral enzyme to
allow for a clinical benefit. Viral resistance development can revert
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this specificity by changing the kinetic properties of the viral
enzyme [12,13]. While a number of enzymatic studies have
revealed crucial insights into the mechanisms of polymerase
inhibition by NAs and the kinetic consequences of resistance
development, an integrated mathematical insight into these
mechanisms has rarely been achieved. In this study, we aim to
mathematically formulate a model of polymerase inhibition by
NAs, by integrating available enzymatic knowledge. The derived
mathematical model should subsequently allow us to assess the
impact of distinct cellular- and molecular determinants of NA
inhibition and to achieve a greater understanding of viral
resistance development and epistatic interactions. Results will be
exemplified for inhibition of DNA polymerization during reverse
transcription (RT) of HIV-1 by nucleoside analog reverse
transcriptase inhibitors (NRTIs).
Initial mathematical modelling efforts in the context of RT
inhibition by NRTIs of HIV-1 were based on the assumption that
incorporation of chain-terminating nucleoside analogs is perma-
nent [14]. The effect of NRTIs was therefore solely explained by
their incorporation probability. In subsequent years after the
introduction of ziduvudine (AZT; the first NRTI against HIV-1),
resistant strains were detected which displayed increased removal
kinetics of AZT from terminated primers [15–17], rather than
discriminating between the natural nucleotide and AZT [18]. This
indicated that nucleoside analog removal is very significant and
constitutes a major resistance pathway against thymidine analogs
(like AZT) and many other NRTIs [13]. The particular
mechanism of resistance to AZT indicated that chain termination
by nucleoside analogs may not be permanent. Hence, a distinct
view on polymerase inhibition by NRTIs is necessary, which
departs from the assumption of permanent chain termination.
Subsequent modeling work [19] used lumped kinetic expressions
and Monte-Carlo simulations instead of deriving analytical
expressions, which precludes the identification of key molecular
determinants of efficacy and drug resistance. Both previous
mathematical modeling efforts were not able to compute the
fitness loss associated with mutations in the RT enzyme, an
important determinant in clinical settings and for studying epistatic
interactions [20–23].
In this work, we present a distinct view of viral polymerase
inhibition by NRTIs, which departs from the assumption of
permanent chain termination. We propose that NRTIs delay the
process of DNA polymerization, rather than permanently
terminating it, simultaneously keeping in mind that any delay of
the process decreases the number of viral progeny and the
likelihood of target cell infection by the virus. The developed
mathematical formulation allows us to study viral polymerase
inhibition by NRTIs as well as fitness effects related to drug
resistance development. By integrating fitness effects and drug
susceptibility, it is further possible to quantify the selective pressure
exerted by NRTIs and to study epistasis. The derived analytical
expressions can be used to study the effects of single- and multiple
NRTIs on DNA polymerization in the absence and presence of
resistance mutations and can be useful for drug design. Chain
termination by NAs may also be reversible in other viruses [24–
26], against which NAs are being developed. Hence, the model
may also be applicable to study NA inhibition of these viruses.
Results
Mechanism of action of nucleoside analogs on DNA
polymerization
A schematic view of the process of viral DNA polymerization in
the presence of NAs is illustrated in Fig. 1. We interpret the
process of DNA polymerization as a Markov jump process with
2:N{1 states (Fig. 1A), where each state in the model corresponds
to the number of incorporated nucleosides: state ‘0’ corresponds to
the initiation of polymerization, states i~1:::N in the model
correspond to the condition in which i nucleosides have been
attached and state 0N 0 corresponds to the final polymerization
product. States ~i correspond to the condition, in which the DNA-
chain consists of i{1 natural nucleosides, but where the last (ith)
molecule in the chain is a chain-terminating nucleoside analog.
At each state i, the nascent DNA-chain can either be shortened
(pyrophosphorolysis reaction rpyro), -prolonged with a nucleoside
(polymerase reaction rpol) or -terminated by a nucleoside analog
(reaction rterm). If the chain has been terminated (state giz1), it can
get released with rate rexc (excision reaction) to produce a chain of
length i. The kinetics of these reactions will be detailed later.
Taking into account the mode of action of chain terminating
nucleoside analogs, we conclude that polymerization will be
decelerated in the presence of these inhibitors, because the overall
time required to go from state ‘0’ (initiation of polymerization) to
state 0N 0 (final polymerization product) in Fig. 1 will be prolonged
in their presence by introducing ‘waiting states’ ~i. The residual
polymerase activity of the wildtype enzyme in the presence of
activated (tri-phosphorylated) nucleoside analogs (1{e(NA,wt))
can thus be expressed as:
1{e(NA,wt)~
T0?N (w,wt)
T0?N (NA,wt)
inhibition of wildtypeð Þ, ð1Þ
where T0?N (w,wt) and T0?N (NA,wt) denote the expected time
to finalize DNA polymerization in the wildtype 0wt0 in the absence
of drugs 0w0 and in the presence of active nucleoside analogs NA
respectively.
Analogously, we can define the effect of chain terminating
nucleoside analogs on some viral mutant, 1{e(NA,mut) and the
fitness loss associated with some mutant in the absence of
treatment w, f (mut):
Author Summary
Nucleoside analogs (NAs) represent an important drug
class for the treatment of viral infections and cancer. They
inhibit DNA/RNA polymerization after being incorporated
into nascent DNA/RNA, which prevents primer extension.
Viruses are particularly versatile and frequently develop
mutations enabling them to avert the effects of NAs. The
mechanisms of resistance development are, however, still
poorly understood. Through mathematical modeling, we
assess the mechanisms by which HIV-1 can develop
resistance against nucleoside analog reverse transcriptase
inhibitors (NRTI). We quantify the effects of treatment and
estimate the fitness of drug resistant mutants. We correctly
predict that HIV-1 can develop resistance by decreasing
NRTI incorporation rate, increasing its excision rate, or
decreasing its affinity for the viral polymerase enzyme. Our
model also allows quantification of the cell specific factors
affecting NRTI efficacy. Resistance development also
changes drug susceptibility distinctly and we show, for
the first time, that selection of drug resistance can occur in
particular target cells. This finding could provide an
explanation of how clinically observed resistant viral
mutants may arise. It also pin-points important parameters
that may impact clinical efficacy of NAs used to treat other
viruses.
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1{e(NA,mut)~
T0?N (w,mut)
T0?N (NA,mut)
inhibition of mutantð Þ ð2Þ
f (mut)~
T0?N (w,wt)
T0?N (w,mut)
fitness of mutantð Þ: ð3Þ
These constituents can be seen as building blocks for describing
the fitness landscape of any arbitrary viral mutant 0mut0 in the
absence- and presence of inhibitors, see e.g. [7,27].
Based on the definitions above, we can also assess the combined
effects of selection and drug pressure for any viral strain, i.e.
f (mut):(1{e(NA,mut)). This allows us to assess the selective
advantage Smut=wt(NA) of a mutant viral strain over the wild type
in an environment that is pharmacologically modified by NAs.
Smut=wt(NA)~
f (mut):(1{e(NA,mut))
(1{e(NA,wt))
~
T0?N (NA,wt)
T0?N (NA,mut)
selective advantageð Þ
ð4Þ
This parameter integrates the (usually opposed) effects of
mutations on resistance and viral fitness. If Smut=wt(NA)v1, the
wild type virus is selected over the mutant strain, whereas
Smut=wt(NA)w1 indicates selection of a mutant virus over the wild
type. Since Smut=wt(NA) depends on the concentration of NAs, a
critical concentration of nucleoside analog NA(mut) can exist,
above which the selection of a particular viral strain over the wild
type is favored. Smut1=mut2(NA)~
T0?N (NA,mut2)
T0?N (NA,mut1)
can also be
used to assess selection between two arbitrary mutant strains mut1
and mut1 in a pharmacologically modified environment.
Finally, we can assess epistatic interactions for combinations of
mutations with regard to viral replication. Briefly, in a two-locus-
two-allele model, epistasis is positive if some double mutant m12
replicates better than expected from the single mutants m1 and m2,
normalized by the replication of the wild type wt (background).
Epistasis is negative if the replication of the double mutant is less
than expected from the single mutants. Along the same lines,
epistasis has been used to study interactions of mutations in the
absence of drugs [22] and for escalating drug concentrations [23].
Using the definitions above, in the presence of NAs, we derive:
ERep:(NA)~ log ((1{e(NA,mut12):f (mut12):(1{e(NA,wt)):f (wt))
{ log ((1{e(NA,mut1)):f (mut1):(1{e(NA,mut2)):f (mut2)): ð5Þ
The equation above becomes positive if the first term is greater that
the second, i.e. the double mutant replicates better than expected
from the single mutants, in agreement with the definition of epistasis
[22,23]. The epistasis term ERep:(NA) defined above regards both
fitness effects and drug resistance. In the absence of drugs,
(1{e)~1, see eqs. (1)–(2) above, we get the fitness epistasis:
Ef (w)~ log (f (mut12):f (wt)){ log (:f (mut1)
:f (mut2)) fitness epistasisð Þ
ð6Þ
It is also possible to only analyze epistatic effects on resistance:
ERes:(NA)~ log ((1{e(NA,mut12):(1{e(NA,wt)))
{ log ((1{e(NA,mut1)):(1{e(NA,mut2)))
resistance epistasisð Þ:
ð7Þ
Note, that the defined terms are additive, i.e. ERep:(NA)~
Ef (w)zERes:(NA).
Figure 1. DNA-polymerization in the presence of chain terminating nucleoside analogs. A: The mathematical model defines a Markov
jump process: Each state in the model corresponds to the number of incorporated nucleotides: state ‘0’ corresponds to the polymerase enzyme
binding to the template, prior to polymerization, states i~1:::N in the model correspond to the condition in which i nucleosides have been attached
and state 0N 0 corresponds to full-length product, after which the enzyme dissociates from the template/primer. States giz1 correspond to the
condition, in which a DNA-chain consisting of i natural nucleosides has been produced, but where the last (iz1th) nucleoside in the chain is a chain-
terminating NA. At each state i, the nascent DNA-chain can either be shortened (pyrophosphorolysis rpyro), -prolonged with a nucleoside
(polymerase reaction rpol) or -terminated by a nucleoside analog (reaction rterm). If the chain has been terminated (state giz1), it can get released with
rate rexc (excision reaction) to produce a chain of length i. B: Sequence context. The reaction rates rpol , rpyro, rterm and rexc depend on the nucleoside
sequence of the template. In the illustration, the next incoming nucleoside could be either a thymidine or a thymidine-analog (corresponding to
position iz1 in the template sequence). Therefore, rpol(iz1) and rterm(iz1) would refer to thymidine- and thymidine-analog incorporation. The
pyrophosphorolysis reaction, on the other hand, would refer to cytosine removal (position i in the primer sequence).
doi:10.1371/journal.pcbi.1002359.g001
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Polymerization of Hetero-Polymeric sequences
The process of DNA polymerization (Fig. 1) defines a birth-
death process. We are interested in the derivation of an explicit
formula for the mean first passage time T0?N (the average time
required to finalize DNA polymerization). Let Ti?iz1 denote the
expected time required to extend the DNA-chain by one
nucleoside (going from state i to state iz1, derivation see eq
(22)–(28); Methods section)
Ti?iz1~(tfiz1:ri?fiz1ztizri?i{1Ti{1?i) 1ri?iz1 : ð8Þ
where ti,tfiz1 are the waiting times in states i and giz1 respectively
and ri?iz1,ri?i{1 are the probabilities to jump from state i to
state iz1 and to state i{1 respectively. The parameter r
i?fiz1
denotes the probability that the chain of length i gets terminated
by incorporation of a nucleoside analog (state giz1). The waiting
times t and jump-probabilities r are defined as follows:
ti~
1
rpol(iz1)zrpyro(i)zrterm(iz1)
, tfiz1~ 1rexc(iz1) ,
ri?iz1~rpol(iz1)
:ti, ri?i{1~rpyro(i)
:ti, r
i?fiz1~rterm(iz1):ti,
ð9Þ
where rpol(iz1) and rterm(iz1) denote the polymerase- and chain
terminating reactions (attachment of the next incoming nucleoside
or its analog), which depend on the efficacy of incorporation of the
respective types of nucleosides (deoxyadenosine, -thymidine,
-guanine or -cytosine triphosphate) or their respective analogs at
position iz1 in the primer, see Fig. 1B. The parameter rexc(iz1)
denotes the rate of release (excision reaction) of a primer that has
been terminated at position iz1 by NA. The parameter rpyro(i)
denotes the pyrophosphorolysis reaction, i.e. the rate at which a
nucleoside is removed from the end of the primer. Note, that t and
r depend on the sequence context because the rates of nucleoside
attachment and -removal depend on the types of nucleosides (and -
analogs) to be incorporated and -removed respectively (see e.g.
Fig. 1B). Eq. (8) allows us to calculate the time to finalize
polymerization recursively, using the relation:
T0?N~
XN{1
i~0
Ti?iz1: ð10Þ
If i~0 corresponds to the unextended primer, we have rpyro(0)~0
in eq. (9) and therefore eq. (8) simplifies to
T0?1~(t~1
:r0?~1zt0)
1
r0?1
, ð11Þ
with t0~
1
rpol(1)zrterm(1)
,t~1~
1
rexc(1)
and r0?1~rpol(1)
:t0,
r0?~1~rterm(1)
:t0, which can be used as a recursion start to
compute the polymerization time.
In the case where no chain-terminating inhibitor is applied, we
have rterm(i)~0 for all i in eq. (9) and therefore eq. (8), and eqs.
(10)–(11) simplify accordingly.
Eq. (8)–(10) can subsequently be used to estimate the residual
polymerase activity in the presence of NAs in the wild type and
any mutant enzyme, using eq. (1) and eq. (2) respectively, to
estimate the fitness of some mutant with regard to polymerization,
using eq. (3), or to estimate the selective advantage of a viral strain
against a competitor, using eq. (4). This will be exemplified in the
next section.
Sequence dependent DNA-polymerization in the presence
of NAs. Using eq. (10), it is possible to compute the average
polymerization time (T0?i) in the absence- and presence of NAs
for any arbitrary sequence to be polymerized. In this section, we
motivate the use of this approach and show how key phenotypic
characteristics can be derived from this simple mathematical
model.
NAs compete with the natural nucleoside substrates for the
same binding site on the polymerase enzyme. We therefore take
into account competitive inhibition for the kinetics of nucleoside-
and nucleoside analog incorporation.
rterm~
kterm:½NA
KD,NA 1z
½dNTP
KD,dNTP
 
z½NA
ð12Þ
rpol~
kpol:½dNTP
KD,dNTP 1z
½NA
KD,NA
 
z½dNTP
ð13Þ
where ½dNTP is the concentration of the deoxynucleoside
triphosphates (adenosine-, thymidine-, cytidine- and guanosine-)
of which the NA is an analog of. The variable ½NA denotes the
concentrations of activated (tri-phosphorylated) nucleoside analog
that competes with its natural nucleoside counterpart for
incorporation into the nascent viral DNA. The parameters kterm
and kpol denote the catalytic rate constants for incorporation of the
NA and the dNTP respectively. KD,NA and KD,dNTP denote the
dissociation constants for NA and dNTP binding to the
polymerase respectively. In the absence of inhibitors w, we have
½NA=0 and therefore eq. (13) and eq. (12) simplify accordingly:
rpol(w)~
kpol:½dNTP
KD,dNTPz½dNTP
, ð14Þ
rterm(w)~0: ð15Þ
Physiological dNTP concentrations for the most important target
cell types of HIV-1 are indicated in Table 1. Parameters for
natural nucleoside DNA- and RNA- dependent polymerization by
wild type HIV-1 reverse transcriptase (RT) are indicated in Table
S1 (supplementary material). In the forthcoming example, we will
analyze the effect of a chain-terminating adenosine analog
(ddATP, the active metabolite of didanosine, ddI) at a fixed
concentration on both single nucleotide incorporation Ti?iz1 (see
eq. (8)) and on cumulative nucleoside polymerization T0?i (see eq.
(10)) for physiological dNTP concentrations in resting CD4z T-
cells (Table 1). Furthermore, we will assess how polymerization is
impaired by the (clinically relevant) ‘K65R’ mutation in reverse
transcriptase in the absence- and presence of ddATP.
In Fig. 2 we have computed the average polymerization time for
a short sequence (indicated on the x-axis in Fig. 2) and typical
parameters for DNA-dependent polymerization for HIV-1 RT,
see Table 1 and Table S1 (supplementary material). In this
example, we have assumed that rpyro~rexc~0:0016s
{1 [17] for
all dNTP and for ddATP respectively. We examine polymeriza-
tion in the absence- or the presence of 1:45mM intracellular
ddATP. The solid black line denotes the polymerization time in
HIV-1 Polymerase Inhibition by Nucleoside Analogs
PLoS Computational Biology | www.ploscompbiol.org 4 January 2012 | Volume 8 | Issue 1 | e1002359
the wild type RT in the absence of ddATP, whereas the blue
dashed- and the red dotted lines indicate the polymerization time
in the presence of ddATP in the wild type and drug-resistant
mutant enzyme (bearing the ‘K65R’ mutation) respectively. The
fold changes in the kinetic parameters, induced by the ‘K65R’
mutation, are stated in Table S2 (supplementary material). In the
wild type enzyme the predicted incorporation probability r
i?fiz1
for ddATP over dATP is 9.4% in the presence of 1:45mM ddATP.
For the ‘K65R’ mutant r
i?fiz1 it is 3.2%. In Fig. 2A one can see
the cumulative time to form the polymerization product T0?i. In
the presence of ddATP, the cumulative polymerization time is
substantially increased (dashed blue line), which is partly
compensated in the drug resistant enzyme bearing the ‘K65R’
mutation (dotted red line). In Fig. 2B we show the single
nucleoside polymerization time Ti?iz1. It can be seen, that in
the presence of ddATP the single nucleoside polymerization time
Ti?iz1 is substantially elevated, in relation to the wild type,
whenever the respective natural nucleoside (here adenosine) needs
to be incorporated (the solid black line vs. the dashed blue line). In
the ‘K65R’ mutant (red dotted line), this is partially compensated
for. However, in the mutant, the single nucleoside polymerization
time Ti?iz1 for incorporation of other nucleosides is also
increased, which indicates, that the ‘K65R’ mutant might decrease
the fitness of the enzyme. We have calculated the fitness of the
mutant enzyme, the residual polymerase activity in the wild type
enzyme -and the ‘K65R’ mutant and the selective advantage of
the ‘K65R’ mutant over the wild type for the presented example,
using eqs (1)–(4). The derived values are stated in Table 2. It can
be seen that the ‘K65R’ mutant decreases ddATP inhibition of
DNA dependent polymerization substantially (the residual poly-
merization is increased from 3.3% to 22.3%). However, the
predicted fitness of the enzyme (in terms of DNA-dependent
polymerization) is reduced to 37.9%. The predicted selective
advantage of the ‘K65R’ mutant is 2.55, indicating that the
‘K65R’ resistance would be selected over the wild type in the
presence of 1:45mM ddATP.
Note, that in this section, we have exemplified the effects of a
particular NA on polymerization, given a specific concentration of
the respective NA and certain kinetic attributes of the polymerase
enzyme (wild type RT vs. ‘K65R’ mutant RT). In the next
sections, we will assess the general impact of certain resistance
mechanisms, by analyzing a range of kinetic parameters and we
will also study the efficacy of NAs for different concentration
ranges.
Molecular determinants of inhibition
While in a hetero-polymeric sequence context, polymerase
inhibition by NAs depends on the particular succession of the
Table 1. Physiological dNTP levels in different cell types.
activated
CD4
z -cells
resting
CD4
z -cells macrophages ref.
dATP 5.1 1.7 0.023 [34]
dTTP 7.9 1.5 0.019 [34]
dCTP 5.9 1.9 0.03 [34]
dGTP 4.5 1.7 0.032 [34]
PPi 79 8 7 [35]
ATP 1400 2200 1600 [35]
All values are expressed in mM.
doi:10.1371/journal.pcbi.1002359.t001
Figure 2. DNA-dependent polymerization of a hetero-polymeric sequence by HIV-1 RT in the presence- and absence of a chain
terminating adenosine analog (ddATP). A: Cumulative time for polymerization of a hetero-polymeric sequence in the presence of a chain-
terminating nucleoside analog (ddATP). The solid black line (filled dots) indicates the cumulative polymerization time up to sequence position i (the
sequence position is indicated at the x-axis) in the absence of inhibitors in the wild type enzyme (calculated using eq. (10)). The dashed blue line
(open squares) indicates the time required for polymerization in the presence of 1:45mM ddATP. The dotted red- and green lines (upward and
downward pointing triangles) show the time required for polymerization in the ‘K65R’ mutant RT enzyme in the presence- and absence of 1:45mM
ddATP. Kinetic parameters are presented in Table 1 and Table S1, S2 (supplementary material) for the wild type and the ‘K65R’ mutant. B: Single
nucleoside incorporation time Ti?iz1 in the absence of ddATP in the wildtype and the ‘K65R’ mutant (solid black and dashed green lines
respectively) and in the presence of ddATP in the wild type enzyme (dashed blue line) and in the mutant enzyme (dotted red line), calculated using
equation eq. (8).
doi:10.1371/journal.pcbi.1002359.g002
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nucleosides, see e.g. Fig. 2B, this is not the case for homo-
polymeric sequences, which consist of only one type of nucleoside,
e.g. poly-adenosine; ‘Poly-A’. This allows us to derive a general,
analytical expression for polymerase inhibition by NAs, which is
valid for any homo-polymeric sequence. We will make use of this
fact to highlight key determinants of inhibition. For assessing the
impact of nucleoside analogs in a particular hetero-polymeric
sequence context, we advice to use eqs. (8)–(11). In a homo-
polymeric sequence, we have rpol(i):rpol,rpyro(i):rpyro,
rterm(i):rterm and rexc(i):rexc for all i. In this particular case,
the explicit solution for the mean first passage time T0?N reads (see
eq. (31)–(32); Methods section)
T0?N (NA)~
rtermzrexc
rexc
 
(rpolzrpyro)
N{1
zrN{1pol
:(N{1)
rNpol
:ð16Þ
When no inhibitor is present (w), we have rterm~0 and thus eq.
(16) simplifies accordingly:
T0?N (w)~
(rpol(w)zrpyro)
N{1
zrpol(w)
N{1:(N{1)
rpol(w)
N
, ð17Þ
where rpol and rpol(w) are the polymerization rates in the presence-
and absence (w) of a competing NA, given in eq. (13) and eq. (14).
Recalling the effect of NAs on polymerization, see eq. (1), we can
derive the residual polymerase activity during NA treatment
on a homo-polymeric sequence, 1{gð Þ~
T0?N (w)
T0?N (NA)
:
1{gð Þ~
rexc
rtermzrexc
rNpol
rpol(w)
N
(rpol(w)zrpyro)
N{1
zrpol(w)
N{1:(N{1)
(rpolzrpyro)
N{1
zrN{1pol
:(N{1)
 ! ð18Þ
The above expression simplifies further, if the pyrophosphorolysis
reaction is very inefficient relative to polymerization, which is the
case for most viral polymerase enzymes; e.g. rpyro%rpolƒrpol(w).
1{gð Þ&
rexc
rtermzrexc|ﬄﬄﬄﬄﬄﬄ{zﬄﬄﬄﬄﬄﬄ}
incorporation & termination
: rpol
rpol wð Þ|ﬄﬄ{zﬄﬄ}
binding competition
ð19Þ
Eq. (19) highlights the two distinct mechanisms by which
inhibition can be conferred, namely a) inhibitor incorporation (and
subsequent quasi-termination of the polymerization reaction) and
b) competition for binding with natural nucleoside substrates. The
efficacy of quasi-termination of the nascent DNA chain depends
on the efficacy of inhibitor incorporation rterm and the duration of
the chain termination, determined by rexc. Binding competition is
solely determined by the fractional decrease of the natural
polymerization reaction (relative to the absence of inhibitor), see
eq. (13).
After substituting the enzymatic rate expressions eqs. (12)–(14)
into equation (19), we can solve for the fifty percent inhibitory
concentration IC50 (see eqs. (33)–(35); Methods section), which
refers to polymerase inhibition in a homo-polymeric sequence (e.g.
‘Poly-A’) and to the intracellular concentration of activated
(triphosphorylated) NA.
IC50&
rexc
ktermzrexc
:KD,NA 1z
½dNTP
KD,dNTP
 
ð20Þ
The above equation highlights the processes, which determine the
efficacy of a chain-terminating nucleoside analog, namely the
kinetic constants kterm,KD,NA and KD,dNTP, the concentration of
natural nucleoside ½dNTP and the excision rate of the inhibitor
rexc.
Cell-specific susceptibility to chain-terminating
nucleoside analogs. Viruses can infect numerous activated-
and resting cells. HIV-1, for example, has been shown to infect
activated- and resting CD4z T-cells, macrophages, dendric cells,
natural killer cells and microglial cells [28–32], and possibly many
more. It is important to understand- and take into account
heterogeneous- or cell specific drug efficacy, as it may be a primary
source of residual viral replication and subsequent resistance
development during treatment [33].
In the context of nucleoside analog efficacy, the major cell-
specific factors (apart from pharmacokinetics), are cell type-, or cell
stage specific dNTP pools (see Table 1) and possibly cell specific
rates of excision rexc. In Fig. 3A, we predicted the impact of cell-
specific ½dNTP contents on DNA-dependent polymerization
during HIV-1 reverse transcription in the presence of ddATP,
using typical kinetic parameters (see Table S1, supplementary
material).
Under the parameters used, a 100 fold increase in dNTP
concentrations would result in a 19 fold increase in the IC50 value
(2:8:10{3 vs. 5:3:10{2mM), whereas a 100-fold decrease in the
dNTP concentrations would only result in a 1.2 fold reduction in
the IC50 value. This is an important observation, because it
indicates that cells that contain high concentrations of dNTP can
confer natural resistance against NRTIs, whereas cells with low
dNTP content, like macrophages [34], do not necessarily confer
hypersusceptibility to NRTIs. This phenomenon can be explained
from eq. (20): The IC50 value does not decrease, if
½dNTP%KD,dNTP.
Resting cells on the other hand might insufficiently phosphor-
ylate NRTIs and subsequently contain lower levels of activated
compound. However, these cells do not simultaneously require
smaller NRTI concentrations for inhibition (IC50 value in Fig. 3A
does not decrease with decreasing dNTP levels). Therefore, resting
cells could constitute reservoirs for residual replication during
antiviral treatment, if NRTI phosphorylation/activation is affect-
ed.
Excision of nucleoside reverse transcriptase inhibitors (NRTIs)
of HIV-1 from terminated primers has been shown to be mediated
by pyrophosphate (PPi) and ATP dependent mechanisms [35].
Whereas ATP concentrations are fairly similar in activated- and
resting lymphocytes, as well as macrophages and monocytes [34–
38] (1 to 5 mM), PPi levels have been shown to vary substantially
Table 2. Efficacy & fitness.
1{e(ddATP,wt) 3.31%
1{e(ddATP,0K65R’) 22.3%
f (0K65R’) 37.9%
SK65R=wt(ddATP) 2.55
Residual DNA-dependent polymerase activity (1{e) of HIV’s RT in resting
CD4z T-cells in the presence of 1:45mM ddATP and fitness (f ) and selective
advantage SK65R=wt with regard to DNA polymerization for the ‘K65R’ mutant.
Calculations are based on formulas (1)–(4).
doi:10.1371/journal.pcbi.1002359.t002
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[35] (8{80mM), see also Table 1. This indicates that IC50 values
for polymerase inhibition by NAs might be cell-specific and may
in some cells lead to incomplete suppression. Here, we did not
analyze the effect of cell-specific PPi and ATP contents, as the
kinetic parameters were not readily available for ddATP. We
however discuss their impact on polymerase inhibition by
zidovudine (AZT) in a subsequent section.
Molecular mechanisms of viral drug resistance against
chain-terminating nucleoside analogs. The enzymatic
properties of a viral polymerase can be adapted in an
evolutionary process to counteract inhibition by NAs. Eq. (20)
indicates that the following three distinct molecular mechanisms
are likely to induce selective resistance against chain-terminating
NAs, and indeed these three mechanisms of resistance have been
described for HIV-1 RT [13].
N selective attrition of inhibitor incorporation (;kterm)
N selective attrition of inhibitor binding to the primer-template
(:KD,NA)
N enhanced excision of the NA from the terminated primer
(:rexc, by e.g. increasing the catalytic efficacy of removal or by
increasing phosphate-donor, e.g. PPi- or ATP- binding).
The consequences of mutational modification of inhibitor
incorporation (kterm) and -binding (KD,NA) with regard to the
predicted efficacy of ddATP are illustrated in Fig. 3B, where we
have used typical parameters for DNA-dependent polymerization
during HIV-1 reverse transcription (see Table S1, supplementary
material). Under the utilized parameters a 100-fold change in the
respective parameter kterm or KD,NRTI leads to a 100-fold change
in the compounds IC50 value. We did not analyze the effect of
enhanced NA excision in Fig. 3B, as the kinetic parameters were
not readily available for ddATP. These effects will be discussed in
the context of polymerase inhibition by zidovudine (AZT) in the
next section.
Mechanism of zidovudine (AZT) resistance by thymidine
analog mutations (TAMs)
It has been argued [17], that the main mechanism of AZT
resistance is due to increased excision of AZT-MP from the
terminated primer. In particular, this process has been shown to
be both pyrophosphate- (PPi) and ATP- dependent in vivo [35]. For
the rate of excision rexc we can therefore write
rexc~
kATP:½ATP
KD,ATPz½ATP
z
kPPi:½PPi
KD,PPiz½PPi
: ð21Þ
The variables ½ATP and ½PPi in the above equation refer to the
concentration of adenosine triphosphate and pyrophosphate and
the parameters kATP and kPPi denote the catalytic rate constants
for (ATP- and PPi dependent) excision. Parameters KD,ATP and
KD,PPi denote the corresponding dissociation constants. The
respective concentrations of PPi and ATP in various cell types
are shown in Table 1 and kinetic parameters for AZT-MP excision
during DNA- and RNA dependent polymerization by HIV-1 RT
(wild type and AZT-resistant mutant) are indicated in Table S3
(supplementary material).
Residual polymerization in the presence of AZT. In
Fig. 4, we have illustrated the predicted concentration-response
relationship for intracellular AZT triphosphate and RNA- and
DNA dependent polymerization of homo-polymeric- (panels A &
B) and hetero-polymeric sequences in unstimulated CD4z T-cells
for the wild type enzyme (solid blue lines) and an AZT-resistant
quadruple mutant (‘D67N/K70R/T215Y/K219Q’; dashed lines),
respectively. From Fig. 4, several conclusions can be drawn: First,
Figure 3. Factors that modify inhibition of DNA polymerization by nucleoside analogs. A: Cell-specific factors: Concentration response
curve of ddATP for wild type RT during DNA-dependent polymerization (homo-polymeric sequence) in unstimulated CD4z T-cells (solid line) and the
impact of a 100-fold variation of the the intracellular nucleoside concentrations (dotted line). The illustration was generated by evaluating eq. (19)
and typical parameters for DNA-dependent polymerization during HIV-1 reverse transcription and its inhibition by ddATP (all parameters are
indicated in Table 1 and Table S1, supplementary material). The corresponding IC50 is depicted by a green filled circle. B: Molecular mechanisms of
drug resistance and hyper-susceptibility (dashed lines). Impact of (i) selective attrition of inhibitor incorporation (;kterm) and (ii) selective attrition of
inhibitor binding to the primer-template (:KD,NA) on drug susceptibility. Hypersusceptibility is conferred by the opposite change in the indicated
parameters. In order to generate the dashed lines, the respective parameters have been increased/decreased by a factor of 100.
doi:10.1371/journal.pcbi.1002359.g003
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as expected, polymerase inhibition by intracellular AZT is more
efficient in homo-polymeric sequences that contain only thymidine
versus hetero-polymeric sequences that contain a mixture of all
four nucleosides (panel A & B vs. C & D). Second, AZT inhibition
of RNA-dependent polymerization is more efficient than
inhibition of DNA-dependent polymerization (panels A & C vs.
panels B & D). Predicted inhibition of RNA-dependent
polymerization of hetero-polymeric sequences is nearly complete
for the wild type and under in vivo intracellular AZT-TP
concentrations (residual activity is ƒ20%, solid blue line and
grey area in Fig. 4C). For DNA-dependent polymerization, we
predict residual activity under in vivo AZT-TP concentrations
(§20%, solid blue line and grey shaded area in Fig. 4D). Third,
the resistance mutations ‘D67N/K70R/T215Y/K219Q’ (dotted
lines) increase the fifty percent inhibitory AZT-TP concentrations.
For DNA-dependent polymerization, the IC50 is shifted to
concentrations that lie beyond clinically achieved concentrations
(see Fig. 4B & Fig. 4D), almost completely diminishing inhibition
by AZT (Fig. 4D). RNA-dependent polymerization is still partially
inhibited in the ‘D67N/K70R/T215Y/K219Q’ mutant in
unstimulated CD4z T-cells (§20% residual polymerization,
Fig. 4A & Fig. 4C).
Cell type specific susceptibility to AZT and impact of
resistance. In Table 3, we have calculated the cell-specific IC50
values for RNA- and DNA dependent polymerization of homo-
polymeric (Poly-‘T’) sequences. Our results indicate that AZT is
much more potent in resting cells (unstimulated CD4z T-cells and
macrophages), as suggested by the smaller IC50 values for the
wildtype in Table 3 (second- and fifth column). This cell-specific
property is mainly due to lower PPi concentrations in resting cells
Figure 4. RNA- and DNA-dependent polymerization in the presence of intracellular AZT triphosphate in unstimulated CD4z T-cells.
The solid blue curves indicate the level of residual polymerization with the wild type enzyme, whereas the dashed lines indicate the residual
polymerization with the ‘D67N/K70R/T215Y/K219Q’ mutant. Panels A & B: Residual RNA- and DNA dependent polymerization of a homo-polymeric
thymidine sequence (Poly-‘T’). Calculations were obtained by solving eq. (19). Panels C & D: RNA- and DNA polymerization of a hetero-polymeric
random sequence of length 500 with 25% respective dNTP content. The illustration was generated using eq. (10). The light grey area indicates the in
vivo concentrations range of AZT in purified circulating CD4z T-cells from [71], converted to units mM by assuming a cell volume of 180mm3 for
resting CD4z T-cells [72]. All utilized parameters are indicated in Tables 1, S1, S2, S3 (supplementary material).
doi:10.1371/journal.pcbi.1002359.g004
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(see Table 1) and subsequently lesser pyrophosphorolysis of AZT-
MP terminated primers in resting cells (see eqs. (20)–(21)) as
discussed previously (section Cell-specific susceptibility to chain-
terminating nucleoside analogs), and is only marginally affected by
lower dNTP levels in resting cells, as decreasing dNTP levels may
not induce hyper-susceptibility as shown in Fig. 3A. The greatest
kinetic change induced by the ‘D67N/K70R/T215Y/K219Q’
affects the catalytic rate of ATP-mediated excision of AZT-MP
from the terminated primer kATP (see Table S3, supplementary
material). This change increases the predicted IC50 of AZT in
unstimulated CD4z cells and macrophages in a much more
pronounced way than in activated CD4z T-cells (fold resistance
w15 in unstimulated CD4z T-cells and macrophages vs. v5 in
activated CD4z T-cells; fourth and seventh columns in Table 3).
In activated T-cells PPi-mediated excision of AZT-MP from the
terminated primer is likely the dominant mechanism, as a
consequence of the much higher PPi concentrations in these
cells (see Table 1). Therefore, increasing kATP will only have a
strong effect once ATP-mediated excision becomes the dominant
mechanism of AZT-removal. Therefore, further increase of kATP
might turn ATP-mediated excision into the main removal
pathway and subsequently impact on resistance in a more
pronounced way in activated CD4z cells as well. Overall, the
IC50 for polymerase inhibition in the ‘D67N/K70R/T215Y/
K219Q’ mutant is probably shifted into concentration ranges
which are rarely achieved in vivo.
Molecular mechanism of AZT-resistance by ATP-
mediated excision. Excision of AZT-MP from the
terminated primer is the major mechanism by which AZT
resistance is thought to be mediated [17]. In particular, ATP-
mediated excision has been discussed as the major in vivo
mechanism of AZT resistance [15,16]. However, at the
molecular level, it is unclear, if the mechanism by which
enhanced excision is achieved is due to an increased removal
rate (parameter kATP in eq. (21)) or increased binding affinity of
ATP to the primer-template (affected parameter: KD,ATP in eq.
(21)). In particular, in a recent paper [39], it was argued, based on
crystal structures of resistant RT, that the main mechanism of
AZT-resistance could be conferred by increasing ATP’s binding
affinity to the resistant RT enzyme. In Fig. 5, we analyze the
impact of the two potential AZT-resistance mechanisms (increased
removal rate kATP vs. decreased KD,ATP). Our predictions show
that increasing the affinity for ATP binding KD,ATP (dashed red
line) does not lead to resistance development under the parameters
used, because ATP binding to the wild type enzyme is already
saturated (KD,ATPv½ATP) at physiological conditions and further
decrease of KD,ATP enhances the saturation effect. However,
increasing the removal rate kATP (dashed blue line) desensitizes
reverse transcriptase-mediated polymerization to AZT inhibition
since rexc&kATP, in cells with low PPi contents and under
saturation conditions (see Table 1 and eq. (21)).
Selection of resistance
Selection of drug resistance depends on the competitive
advantage of some resistant mutant over its competitors (either
the wild type or some competing viral mutant) in a particular
environment. In order to quantify whether drug resistant mutants
become selected in an environment that is modified by NAs, we
have previously defined the selective advantage S in eq. (4) (and
paragraph below).
Selection of thymidine associated mutations (TAMs) by
AZT in different cell-types. In Fig. 6A and Fig. 6B, the
selective advantage of TAMs over the wild type
STAM=wt(AZT-TP) is shown for RNA-dependent polymerization
(panel A) and DNA-dependent polymerization (panel B)
respectively in distinct cell-types relevant to HIV-1 infection
(solid green-, blue and red lines indicate STAM=wt(AZT-TP) for
activated CD4z T-cells, resting CD4z T-cells and macrophages,
respectively). The respective threshold concentrations AZT
(TAM) above which resistance becomes selected, STAM=wt
(AZT-TP)w1, are 5:4:10{4mM (resting CD4z cells)
v6:3:10{4mM (macrophages) v7:3:10{3mM (activated CD4z
cells) for RNA-dependent polymerization. For DNA-dependent
polymerization, the corresponding thresholds are 6:2:10{3mM
(macrophages) v0:01mM (resting CD4z cells) v0:36mM
(activated CD4z cells).
Table 3. Cell-specific IC50 values of AZT-TP for ‘poly-
thymidine’ polymerization and susceptibility change by
resistance development.
RNA/DNA DNA/DNA
cell type ‘wt’ ‘res’*
fold
res. ‘wt’ ‘res’*
fold
res.
act. CD4z 2:4:10{3 1:10{2 4.5 6:6:10{2 2:7:10{1 4.1
rest. CD4z 2:7:10{4 4:2:10{3 15.7 6:8:10{3 1:5:10{1 22.6
macr. 2:3:10{4 3:9:10{3 17.2 5:4:10{3 1:2:10{1 22.5
IC50 values, expressed in mM, were calculated using eqs. (20)–(21). Cell-specific
parameters were taken from Table 1. All kinetic parameters were taken from
Table 1 and Tables S1, S2, S3 (supplementary material).
*‘res’ = D67N/K70R/T215Y/K219Q mutant.
doi:10.1371/journal.pcbi.1002359.t003
Figure 5. Molecular mechanisms of HIV-1 resistance develop-
ment against AZT by ATP-mediated excision. Potential mecha-
nisms for resistance development against AZT through increasing its
excision rate rexc via an ATP-mediated mechanism (see eq. (21)). We
calculated residual DNA-dependent polymerization of a Poly-T
sequence in unstimulated CD4z T-cells using eq. (19) with parameters
from Tables 1, S1 and S3 (supplementary material). The solid black line
shows residual DNA polymerization (1{g) in the wild type virus,
whereas the dotted red line and the dashed blue line refer to residual
polymerization if KD,ATP and kATP were decreased- and increased 100-
fold respectively.
doi:10.1371/journal.pcbi.1002359.g005
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Two major findings can be derived from Fig. 6: Firstly, it can be
seen that in the case of RNA-dependent polymerization, the
‘D67N/K70R/T215Y/K219Q’ mutation becomes selected
(STAM=wt(AZT-TP§1; dashed horizontal black line) at lower
intracellular AZT-TP concentrations (below clinically achieved
concentrations in resting CD4z T-cells and macrophages; light
grey area) compared to DNA-dependent polymerization. During
DNA-dependent polymerization, ‘D67N/K70R/T215Y/K219Q’
is only selected at clinically relevant levels of AZT-TP (resting
CD4z T-cells and macrophages) or far above (activated CD4z
T-cells). We have shown previously in Fig. 4C & D that inhibition
of RNA-dependent polymerization by AZT-TP is much more
efficient compared with inhibition of DNA-dependent polymeri-
zation (see also Table 3), explaining the higher selective pressure
exerted at lower AZT-TP concentrations during RNA-dependent
polymerization. Therefore, we would expect that resistance is
favored at lower concentrations during RNA-dependent polymer-
ization, when compared to DNA-dependent polymerization.
Secondly, and quite surprisingly, Fig. 6A & B indicate that
resistance to AZT may not become selected over the wildtype in
activated CD4z cells as it only confers a very small selective
advantage in these cell types during RNA-dependent polymeriza-
tion and at clinically relevant concentrations of AZT-TP (solid
green line and grey area in Fig. 6A). For DNA-dependent
polymerization the selection parameter indicates a disadvantage
(STAM=wt(AZT-TP)v1) of the ‘D67N/K70R/T215Y/K219Q’
mutant at clinically relevant AZT-TP concentrations. In resting
CD4z T-cells and macrophages on the other hand, resistance
selection is favored at clinically relevant AZT-TP concentrations
(DNA-dependent polymerization) and below (RNA-dependent
polymerization). These results indicate, that selection of the
‘D67N/K70R/T215Y/K219Q’ mutation by AZT is cell-specific
and may preferably occur within resting CD4z T-cells and
macrophages, whereas resistance selection in activated CD4z T-
cells is less likely. This finding, however, warrants further
investigation of the intermediate strains in the TAM resistance
pathway, once kinetic data becomes available.
Subsequent selection of Q151M-complex mutations by
TDF. The selective advantages of intermediate viral strains of
the Q151M-complex (multi-drug) resistance pathway (Q151M,
A62V/V75I/F77L/F116Y/Q151M (Q151Mc) and Q151Mc/
K70Q ) with respect to increasing tenofovir diphosphate (TFV-
DP) concentrations are shown in Fig. 7 for DNA-dependent
polymerization in resting CD4z T-cells. Panel A shows the
selective advantage of the respective mutant in relation to the wild
type, i.e. SQ151M=wt(TFV-DP) (dashed blue line), SQ151Mc=wt
(TFV-DP) (solid green line) and SQ151MczK70Q=wt(TFV-DP)
(dotted magenta line). At in vivo concentrations ranges of TFV-DP
(light grey area) the selective pressure towards the Q151M and the
Q151Mc strains is relatively weak (1vSQ151M=wt(TFV-DP)ƒ
SQ151Mc=wt(TFV-DP)v3), whereas it is strong for the Q151Mc/
K70Q mutant (4vSQ151MczK70Q=wt(TFV-DP)v10). It can be
seen that the selective advantage is of the order SQ151M=wt(TFV-
DP)ƒSQ151Mc=wt(TFV-DP)vSQ151MczK70Q=wt(TFV-DP), indi-
cating a distinctly graded ‘selection landscape’ from the wild type
towards the Q151Mc/K70Q mutant. A graded landscape would
imply that the presence of TFV-DP favors subsequent resistance
mutations in the resistance pathway. We therefore further
analyzed the form of the ‘selection landscape’ in panel B, where
we have plotted the selective advantage of the respective mutants
in relation to their progenitors in the resistance pathway, i.e.
SQ151M=wt(TFV-DP), SQ151Mc=Q151M(TFV-DP), SQ151MczK70Q=
Q151Mc(TFV-DP). It can be seen that the Q151M single
mutation has a weak selective advantage over the wild type (S&2
dashed blue line). The Q151M-complex (Q151Mc) has an even
weaker selective advantage over the Q151M single mutation in the
presence TFV-DP (Sv1:5, solid green line). However, the
subsequent mutation, Q151Mc?Q151Mc=K70Q has a strong
Figure 6. Selective advantage of the ‘D67N/K70R/T215Y/K219Q’ mutant against the wild type during RNA- and DNA-dependent
polymerization in the presence of AZT-TP. The solid lines (green= activated CD4z cells, blue =unstimulated CD4z cells, red =macrophages)
indicate the selection parameter STAM=wt(AZT-TP), defined in eq. (4), for different levels of intracellular ATZ-TP during RNA- and DNA dependent
polymerization (Panels A & B) of a random sequence of length 500 with 25% respective dNTP content. The light grey area indicates the in vivo
concentrations range of AZT in purified circulating CD4z T-cells from [71], converted to units mM by assuming a cell volume of 180mm3 for resting
CD4z T-cells [72]. The dashed horizontal line indicates the threshold for resistance selection, i.e. S~1. All utilized parameters are indicated in Table 1
and Tables S1, S2, S3 (supplementary material).
doi:10.1371/journal.pcbi.1002359.g006
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selective advantage in the presence of TFV-DP (Sw2). The
selection landscape therefore exhibits a slight increase
(wt?Q151M), followed by a plateau (Q151M?Q151Mc),
followed by a steep increase (Q151Mc?Q151Mc=K70Q). Our
analysis indicates that TDF treatment slightly favors Q151M over
the wild type, it, however, does not favor the Q151M-complex
SQ151Mc=Q151M(TFV-DP)&1. Once the Q151M-complex has
arisen (due to co-administered drugs), TDF could select for the
K70Q mutation.
Epistasis
Epistasis has been used to describe the phenomenon where the
phenotype of one mutation is modified by one or several other
mutations [22,23]. In a two-locus-two allele model, epistasis is said
to be positive when the combined effects of a double mutant result
in greater replication than expected if the effects on replication
coming from the two single mutations were independent.
Conversely, epistasis is said to be negative, when the combined
effects of a double mutant result in lesser than expected
replication. Resistance mutations against NRTIs of HIV-1 are
located within the same gene (the Pol gene). It is therefore likely,
that the combination of mutations produce a phenotype that has
unexpected/novel properties. The intention of this analysis is to
elucidate how epistasis depends on the environment in which the
virus replicates (and which is altered by NAs), analogously to [23].
In Fig. 8, we assessed epistasis with regard to replication (solid blue
line), fitness (solid red line) and resistance (solid green line), based
on eqs. (5)–(7) for the K65R/M184V mutant and varying TFV-
DP concentrations for DNA-dependent polymerization in resting
CD4z T-cells.
It can be seen that epistasis in the absence of drugs Ef (w) (fitness
epistasis) is positive (solid red line). This result is based on the fact
that the predicted fitness of the double mutant fM184V=K65R~30%
is larger than expected if the fitness effects coming from the
respective single mutants fM184V~46% and fK65R~38% were
independent. Resistance epistasis ERes:(NA) (green line) on the
other hand is negative at clinically relevant TFV-DP concentra-
tions (light grey area). Whereas the M184V mutation is slightly
hypersusceptible (predicted fold resistance relative to the wild type:
0.76 see also [40]), the K65R mutation confers &5:3-fold
resistance in relation to the wild type, mainly by decreasing
TFV-DP’s incorporation rate kterm, see Table S2 (supplementary
information). We predicted that the double mutant ‘M184V/
K65R’ is &2-fold resistant in relation to the wildtype. Resistance
epistasis ERes:(NA) thus reduces replication of the double mutant
in the presence of TFV-DP and is negative. The combined effects
of fitness and drug resistance are indicated by the blue line in
Fig. 8. Our predictions indicate that epistasis is positive at clinically
relevant TFV-DP concentrations (light grey area), because the
(positive) fitness epistasis overweighs the negative resistance
epistasis in the clinically relevant range of TFV-DP concentra-
tions. At higher TFV-DP concentrations, however, the negative
resistance epistasis overweighs.
Residual DNA-dependent polymerization of mutant
reverse transcriptase (RT) of HIV-1 in the presence of
distinct nucleoside reverse transcriptase inhibitors
(NRTIs)
Viral fitness is an important determinant for the pre-treatment
abundance of drug resistant mutants and their persistence in
circulating virus after withdrawal of drugs. Moreover, it has also
important implications for the therapeutic strategy and on disease
progression [20,21]. For these reasons, we assessed viral fitness of
the distinct mutants in the absence of drugs. We estimated viral
Figure 7. Selective advantage S of intermediate viral mutants of the Q151M-complex during DNA-dependent polymerization in the
presence of TFV-DP. Dashed blue-, solid green- and dotted magenta line indicate the selective advantage of the Q151M, the multi-drug resistant
Q151M-complex (Q151Mc: A62V/V75I/F77L/F116Y/Q151M) and the Q151Mc+K70Q mutation during DNA-dependent polymerization of a random
sequence of length 500 with 25% respective dNTP content in unstimulated CD4z cells. The light grey area indicates the in vivo concentrations range
of TFV-DP from [56,71,73], converted to units mM by assuming a cell volume of 180mm3 for resting CD4z T-cells [72]. The dashed horizontal line
indicates the threshold for resistance selection, i.e. S~1. Panel A: Selective advantage of the respective mutants with regard to wild type
Smut=wt(TFV-DP). B: Selective advantage of a succeeding mutants with regard to progenitor in Q151M complex formation Smut1=mut2(TFV-DP). All
utilized parameters are indicated in Table 1 and Tables S1, S2 (supplementary material).
doi:10.1371/journal.pcbi.1002359.g007
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fitness on the basis of the relative decrease in polymerization time,
see eq. (3), for a hetero-polymeric sequence context and based on
DNA-dependent polymerization during reverse transcription. The
results are presented in Table 4 (bottom row). The fitness of the
viral mutants was of the order K65R=M184VvK65Rƒ
M184VvQ151M&wildtype and is in general agreement with
published data on viral fitness [21,41]. Notably, the K65R and
M184V mutants conferred substantial fitness losses, which
explains the low prevalence of K65R even in treatment
experienced patients [21], and M184V reversion to wild type
when 3TC, ABC or FTC are eliminated from second or third-line
anti-retroviral regimens [42].
Estimated residual DNA-dependent polymerization for mutant
and wild type RT under in vivo concentration ranges of tripho-
sphorylated NRTIs in resting CD4z T-cells and on a hetero-
polymeric sequence context (using eqs. (1)–(2)) are presented in
Table 4. Utilized kinetic parameters for nucleoside incorporation
are provided in Table S2 (supplementary material). We predicted
that most inhibitors decreased DNA-dependent polymerization to
values of 2–25% in the wildtype enzyme. However, 3TC displayed
superior efficacy (only 1.5–5% residual polymerization) and AZT
only poorly inhibited DNA-dependent polymerization. However,
as discussed in section Residual polymerization in the presence of AZT,
AZT is likely to exert its main effect through inhibition of RNA-
dependent polymerization. The Q151M mutation decreased the
efficacy of carbovir triphosphate (CBV-TP) markedly (8 fold) and
had only marginal impact on tenofovir diphosphate (TFV-DP),
whereas lamivudine triphosphate (3TC-TP) and emtricitabine
triphosphate (FTC-TP) were unaffected (see also [40,43]).
Combination treatment with 3TC-TP+CBV-TP could, however,
restore inhibition of polymerization and combination treatment
FTC-TP+TFV-DP was very efficient, however not markedly
different from FTC-TP alone. The M184V mutation decreased
susceptibility to 3TC-TP (&20 fold) and CBV-TP (8 fold), having
marginal impact on stavudine triphosphate (d4T-TP) and no effect
on TFV-DP, which is consistent with phenotypic measurements
[40,43]. Susceptibility to the combination of d4T-TP+3TC-TP
was comparable to d4T-TP alone. The efficacy of 3TC-TP+CBV-
TP was strongly reduced. We predicted that the K65R mutation
reduced the impact of 3TC-TP, FTC-TP and TFV-DP (7-, 4 and
3-fold respectively) and also reduced the susceptibility to the
combination FTC-TP+TFV-DP (5-fold), consistent with pheno-
typic measurements [40,43]. The double mutation K65R/M184V
conferred complete resistance to 3TC-TP and near complete
resistance to FTC-TP and partly restored susceptibility to TFV-
DP or TFV-DP+FTC-TP, compared to K65R alone, in
agreement with phenotypic measurements [40,43].
Inhibition of human mitochondrial polymerase{c by
various NRTIs
Despite their antiviral activity, NRTIs have been reported to
cause severe mitochondrial toxicity [9,44], limiting their thera-
peutic use. A dominant hypothesis for the manifestation of
mitochondrial toxicity by NRTIs is that NRTIs inhibit polymer-
ase-c (pol{c) function, which is necessary to duplicate the
mitochondrial genome, thereby leading to mtDNA depletion and
subsequent mitochondrial abnormalities. The anticipated mecha-
nism of pol{c inhibition is highly similar to inhibition of
polymerization during reverse transcription: tri-phosphorylated
NRTIs compete with endogenous dNTPs for incorporation into
the nascent mtDNA, and, once incorporated, lead to quasi-chain
Figure 8. Epistatic interactions for DNA-dependent polymeri-
zation in the presence of TFV-DP. Solid blue-, green- and red line
indicate epistasis with regard to replication ERep:(NA), resistance
ERes:(NA) and fitness Ef (w) as defined in eqs. (5)–(7) for the double
mutant ‘K65R/M184V’. The black dashed horizontal line indicates the
value, where no epistatic interactions occur. The light grey area
indicates the in vivo concentrations range of TFV-DP from [56,71,73],
converted to units mM by assuming a cell volume of 180mm3 for
unstimulated CD4z T-cells [72]. All utilized parameters are indicated in
Table 1 and Tables S1, S2 (supplementary material).
doi:10.1371/journal.pcbi.1002359.g008
Table 4. Estimated in vivo % residual DNA-dependent
polymerization (1{e) for distinct mutants and drug
combinations.
wt Q151M M184V K65R
M184V/
K65R
TFV-DP 4.16–24.11 9.20–42.55 3.32–20.05 19.11–63.34 8.72–41.14
AZT-TP 29.47–80.69 - - - -
d4T-TP 2.08–25.95 - 7.44–56.97 - -
FTC-TP 2.07–21.45 1.24–14.00 - 21.28–77.76 47.37–92.09
3TC-TP 1.54–4.95 0.86–2.81 51.22–77.71 12.29–31.77 86.19–95.40
CBV-TP 7.63–14.18 82.27–90.27 45.49–62.53 - -
FTC-TP 1.39–12.69 1.11–11.75 - 11.02–53.12 7.80–39.22
+TFV-DP
d4T-TP 0.91–4.40 - 7.01–49.20 -
+3TC-TP
CBV-TP 1.33–3.89 0.87–2.84 32.20–53.53 - -
+3TC-TP
CBV-TP 1.27–3.81 - - - -
+3TC-TP
+AZT-TP
fitness 100 100 46 38 30
In vivo concentration ranges were 3TC-TP = 12.2–40.5; FTC-TP = 1.5–19.4; TFV-
DP= 0.16–1.17; CBV-TP = 0.44–0.88; d4T-TP = 0.034–0.56; and AZT-TP = 0.0056–
0.056 mM respectively [56,71,73–75], assuming an average cell volume of
180mm3 for resting CD4z T-cells [72].
doi:10.1371/journal.pcbi.1002359.t004
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termination [9]. Polymerase-c can perform two crucial catalytic
functions, namely DNA polymerization and exonuclease activity;
the later enabling the removal of incorporated NRTIs. The
mechanism of action of NRTIs on pol{c leads us to believe that
our mathematical model of polymerase inhibition by NAs can be
useful in predicting NRTI-induced inhibition of pol{c.
Utilizing pre-steady state kinetic data for the incorporation of
dNTPs and various NRTIs (see Table S4, supplementary material),
we estimated the residual pol{c function in a hetero-polymeric
sequence context and under concentration ranges of NRTI-TPs
typically observed in vivo. The results are stated in Table 5. For
simulation purposes we utilized eqs. (1) and assumed dNTP levels
typically observed in unstimulated CD4z cells (see Table 1). Under
the parameters used, we found that mtDNA polymerization is
substantially inhibited in the presence of d4T-TP and moderately
inhibited by 3TC-TP for in vivo -triphosphate concentration ranges.
Similarly, combinations 3TC-TP+D4T-TP reduced pol{c activity
substantially and 3TC-TP+CBV-TP or 3TC-TP+AZT-TP+CBV-
TP reduced pol{c activity moderately. We found the following
order of inhibition of polymerase-c : d4T{TPw3TC{TPw
TFV{DP§FTC{TP§AZT{TP§CBV{TP, which agrees
with experimental findings [9]. The mitochondrial toxicity of AZT
is likely not due to pol{c inhibition. Instead, it has been explained
in terms of various other mechanisms, which are exemplified in the
Discussion section.
We subsequently defined a therapeutic index as the ratio of the
mean inhibition of pol{c and wild type RT respectively. The
therapeutic index indicated the following order for the inhibitors and
their combinations: d4T{TPvd4T{TPz3TC{TPvTFV{
DPvFTC{TPƒCBV{TPvFTC{TPzTFV{DPv3TC{
TPvCBV{TPz3TC{TP. Note, that AZT has been excluded
from this assessment, because its mitochondrial toxicity has been
contributed to mechanisms other than pol{c inhibition (see
Discussion section).
Discussion
We presented a novel mechanistic mathematical model of HIV-
1 polymerase inhibition by NAs that, for the first time, focussed on
the transient aspect of this inhibition. This is an important
characteristic, as HIV-1 can exploit the transient nature of
inhibition by reducing the residence time of the apparent chain
terminator (the incorporated NA) in the nascent viral DNA to
achieve drug resistance (summarized in [13]). NA removal from
quasi-terminated RNA/DNA chains has also been described for
hepatitis B & C viruses [24–26]. Hence, the developed model may
also be applicable to study polymerase inhibition by NAs in these
viruses. In contrast to previous mathematical approaches [14,19],
we therefore describe the effects of nucleoside analogs on DNA-
polymerization in terms of an increase in the average polymer-
ization time, which is analogous to a reduction of the overall
polymerization rate, i.e. npoly(w)~1=T0?N (w). This mathematical
approach not only allows to study various resistance mechanisms,
but also allows for the first time to estimate the inherent fitness of
drug resistant mutants, resulting from microscopic changes in the
polymerization rate constants (e.g. kpol, KD,dNTP) of the mutant
viral enzyme (see eqs. (1)–(3)). The derived model can readily be
used to assess the probability to successfully finish polymerization.
In supplementary Text S1 we have given an example for HIV-1
reverse transcription. It is also explained therein how the model
can be integrated in larger (systems biology) models of the viral life
cycle in order to study the effects of NAs.
The developed model can be parameterized in terms of
physiological parameters (such as dNTP concentrations) and
microscopic kinetic rates (e.g. kpol, kterm, KD), typically derived
from cell-free in vitro assays. These parameters can usually be
precisely determined with standard errors v20%. We demon-
strated the applicability of the model for various distinct
polymerization processes, in particular for polymerase inhibition
during HIV-1 RT and mitochondrial pol{c by NRTIs,
respectively. Adaptation to distinct polymerization processes was
achieved by utilizing the kinetic constants for the respective
processes, while the model remained unchanged. Notably, model-
predicted macroscopic predictions (viral fitness, drug efficacy and
toxicity) were consistent with various experimental macroscopic
findings and thus underline the usefulness of the proposed model.
Based on the developed model of polymerization and its
inhibition by NAs, we derived two sets of mathematical solutions:
Eqs. (1)–(11) can be used to compute the average effect of NAs and
combinations of NAs on polymerization of arbitrary (hetero-
polymeric) DNA sequences. Analogously, these equations can be
used to determine the deceleration of polymerization resulting
from resistance mutations in the absence of any NA, as an
indicator of their inherent fitness cost. On the other hand, eqs.
(16)–(20) represent analytical solutions for polymerase inhibition
by NAs in a simplified homo-polymeric sequence context. The
resulting equations (19)–(20) immediately highlight key determi-
nants of NA inhibition and resistance development in this context.
These equations can also be used to determine the model’s
sensitivity for different combinations of kinetic- and physiological
parameters, see Fig. 3 and Fig. 5. Based on eqs. (19)–(20), we
found that factors impacting on NA inhibition can generally be
divided into two categories: (i) kinetic- and (ii) cellular factors.
Eq. (20) revealed that the rate of NA incorporation kterm, its
binding affinity KD,NA and the catalytic rate of NA removal rexc
are key molecular kinetic determinants for the efficacy of NAs. All
indicated molecular kinetic determinants (kterm, KD,NA and rexc)
depend on the viral polymerase enzyme and are thus prone to
resistance development. The impact of alterations in these
Table 5. Estimated in vivo % residual human mitochondrial
polymerase-c activity in resting CD4z cells.
(1{etox) ther. Index
*
TFV-DP 63.54–92.72% 5.5
AZT-TP 98.74–99.87% {
d4T-TP 0.15–2.40% 0.1
FTC-TP 94.05–99.51% 8.2
3TC-TP 25.69–53.43% 12.2
CBV-TP 98.78–99.38% 9.1
FTC-TP/TFV-DP 61.96–92.55% 11
3TC-TP/d4T-TP 0.16–2.48% 0.5
CBV-TP/3TC-TP 25.18–52.70 14.9
CBV-TP/3TC-TP/AZT-TP 26.22–54.13% {
In vivo concentration ranges were 3TC-TP = 12.2–40.5; FTC-TP = 1.5–19.4; TFV-
DP= 0.16–1.17; CBV-TP = 0.44–0.88; d4T-TP = 0.034–0.56; and AZT-TP = 0.0056–
0.056 mM, respectively [56,71,73–75], assuming an average cell volume of
180mm3 for resting CD4z T-cells [72].
*calculated as the ratio of average effect on polymerase-c and wildtype reverse
transcriptase of HIV-1: (1{etox)=(1{eRT{wt).
{mitochondrial toxicity of AZT has been attributed to mechanisms other than
pol{c inhibition (see Discussion section).
doi:10.1371/journal.pcbi.1002359.t005
HIV-1 Polymerase Inhibition by Nucleoside Analogs
PLoS Computational Biology | www.ploscompbiol.org 13 January 2012 | Volume 8 | Issue 1 | e1002359
parameters is illustrated in Fig. 3B for ddATP and in Fig. 4 & 5 for
AZT-TP.
Various reports indicate cell-specific differences in NA efficacy
against HIV-1 [45–47]. Differences in efficacy were often
brought in association with intracellular NA-TP:dNTP ratios
[48,49]. Utilizing the derived model, we elucidated the impact of
cellular factors on HIV-1 RT polymerase inhibition by NRTIs.
Quite surprisingly, we found that cells that contain low dNTP
content do not necessarily confer hypersusceptibility to NRTIs if
½dNTP%KD,dNTP (see Fig 3A). For AZT, we predicted that
alteration of PPi and ATP levels can have a strong impact on its
efficacy (see Table 3). In summary, we demonstrated that the
concurrence of multiple kinetic- and physiological factors, rather
than a single parameter, can determine the susceptibility of an
infected cell towards NAs, see eq. (20)–(21). In addition to cells
that contain an unfavorable NA-TP:dNTP ratio [48,49], cells
that contain high levels of PPi or ATP and low levels of NA
(regardless of their dNTP content) could be resistant to NRTI
treatment and residual viral replication despite treatment could
persist in these cells as well. This finding can have important
consequences for HIV-1 treatment with NRTIs, as HIV-1
exhibits a broad cell tropism [28–32]: While some evidence for
low-level ongoing replication in the context of apparently
suppressive antiviral therapy has been reported [50], the cellular
source remains to be determined [51]. Whereas it has been
shown previously [33], that heterogeneous viral inhibition
facilitates drug resistance development, we show evidence for
cell-specific (thus heterogeneous) inhibition by NRTIs. Thus, a
possible mechanism for the emergence of drug resistance against
could be explained on the basis of the mechanism of action of
these compounds. However, further evidence is required to
confirm this hypothesis.
We analyzed the specific mechanisms of AZT resistance
through TAMs. It is well known, that TAMs induce resistance
through increasing the excision of incorporated NAs from nascent
viral DNA. However, the precise mechanism that increases
excision is controversial. A recent crystal structure of resistant
RT [39], showed that the orientation of ATP is altered in the
mutant enzyme. Based on this structure [39], the authors argued
that ATP, which serves as an excision substrate for incorporated
AZT, would bind with higher affinity to the quasi-terminated
nascent viral DNA, accelerating the removal of incorporated AZT.
To the contrary, our kinetic model indicated that increasing the
affinity for ATP binding KD,ATP does not lead to resistance
development (see Fig. 5), because ATP binding to the wild type
enzyme is already saturated (KD,ATPv½ATP) at physiological
conditions, and further decrease of KD,ATP enhances the
saturation effect. Increasing the removal rate kATP desensitizes
reverse transcriptase-mediated polymerization to AZT inhibition
since rexc&kATP, in cells with low PPi contents and under
saturation conditions (see Table 1 and eq. (21)). We therefore
propose that the main kinetic resistance effect of the altered
orientation of ATP in mutant RT is mediated by an increased
removal rate kATP, in agreement with a pre-steady state kinetic
analysis [17], although binding could be affected. In particular, the
crystal structure showed that the resistance mutations affect the
positioning of ATP in the RT catalytic site [39], which must
translate into an effect on kATP.
We quantified the inhibitory effects of AZT during RNA- and
DNA dependent polymerization and we analyzed how TAMs
(‘D67N/K70R/T215Y/K219Q’) induce susceptibility changes.
We found that AZT inhibition during HIV-1 reverse transcription
is more efficient during RNA-dependent polymerization than
during DNA-dependent polymerization, see Fig. 4. Moreover,
inhibition, as well as susceptibility changes induced by TAMs were
found to be cell-specific (see Table 3).
While the emergence of a particular viral strains depends on a)
the probability that the mutant is generated (related to residual
replication and genetic distance), it also critically depends on the
likelihood that the generated mutant becomes selected subse-
quently. However, if inhibition- and selection forces are different
in distinct target cells (see Table 3 and Fig. 6), then the processes of
mutant strain generation and subsequent selection might also we
divided among target cells. We therefore further looked at the
selective advantage STAM=wt of the ‘D67N/K70R/T215Y/
K219Q’ mutant in distinct cell types. Specifically, we predicted
that the selective advantage of the ‘D67N/K70R/T215Y/
K219Q’ mutation in the presence of AZT at clinically relevant
concentrations is quite distinct in activated CD4z cells, resting
CD4z cells and macrophages (see Fig. 6). We found that the
‘D67N/K70R/T215Y/K219Q’ mutation is less likely selected
over the wild type in activated CD4z cells, whereas this mutation
is preferred in resting CD4z cells and macrophages (see Fig. 6) at
clinically relevant concentrations. While these results indicate, for
the first time, that selection forces against NA treatment can be
quite distinct for diverse target cells, a detailed analysis of the
various intermediate mutants in the TAM resistance pathway is
required, in particular a construction of the ‘selection landscape’
for particular mutants in the resistance pathway and for different
cell types infected with HIV-1 in the presence of combinations of
drugs to fully understand resistance dynamics in vivo. The
developed model can be used to facilitate such an analysis: In
Fig. 7, we started to reconstruction the ‘selection landscape’ for
intermediate mutants of the Q151M-complex during TDF
treatment in unstimulated CD4z cells. We found for this cell
type, that TDF alone is unlikely to select the Q151M-complex
over the Q151M single mutation. Once the Q151M-complex has
arisen, however, TDF would select for the additional K70Q
mutation. An extended analysis of the resistance pathways in the
case where particularly large genetic barriers are involved may in
the future help to understand and influence the dynamics of
resistance emergence for e.g. TAMs and the Q151M complex.
Epistasis has been suggested as a method to study evolutionary
dynamics of virus populations [52]. It describes the phenomenon
where the replicative fitness of one mutation is modified by one or
several other mutations [22,23]. Epistasis is said to be positive
when the combined effects of two-or-more mutations result in
greater replication than expected if the effects coming from the
two single mutations were independent. Since resistance mutations
against NRTIs of HIV-1 are located within the same enzyme
(RT), several mutations could modify the enzyme in unexpected
ways, i.e. result in epistatic interactions with regard to fitness and
resistance. We have shown in Fig. 8 that our model can be used to
analyze different aspects of epistasis (fitness, resistance and
replication). In the presented example, we detected positive fitness
epistasis Ef of the ‘M184V/K65R’ double mutant and negative
resistance epistasis ERes(NA) with increasing TFV-DP concentra-
tions in comparison with the single mutations. The combined
effects of fitness- and resistance were positive at relevant
concentration ranges of TFV-DP. The major conclusion from
this analysis is that the combination of mutations can alter the RT
enzyme in unexpected ways. The phenotypic attributes of a
multiple mutated strain may not be intuitively related to the
attributes of the single mutants. It is thus required to view each
multiple mutated strain as an independent entity with regard to
resistance and fitness. For deriving information about intermediate
viral mutants in a resistance pathway (e.g. the Q151M-complex, or
TAMs), it is therefore necessary to measure the attributes of each
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intermediate strain independently. Related experimental work
[23] indicated that replication ranking, rather than epistasis
predicts dynamics of resistance emergence, in line with our
analysis in section ‘‘Selection of Resistance’’.
Based on the developed model, we predicted that the ‘D67N/
K70R/T215Y/K219Q’ mutation induces a 4.1 to 22.6 fold
increase in the IC50 value for poly-thymidine polymerization,
depending on the cell type and the template (RNA or DNA). In
cellular assays, the ‘D67N/K70R/T215Y/K219Q’ mutant can
induce a 120–150 fold increase in the fifty percent inhibitory
(extracellular) concentration when measured in CD4z HeLa-cells
[46] and a 8000 fold increase in MT-4 human T-lymphoid cells
[47], respectively, while at the same time resistance at the
enzymatic level was observed to be far more moderate [47]. This
indicates that a direct quantitative comparison of susceptibility
changes observed in different cell-based assays and changes
computed at the enzymatic level, e.g. on the basis of DNA-
dependent polymerization in resting CD4z cells (see Table 3)
might not be possible. Here, we summarize a few mechanisms,
which could contribute to this difference: (i) Firstly, the cell types
utilized in distinct cell-based assays differ, which can results in
distinct susceptibility changes to NRTIs. We discussed- and
illustrated the impact of these cell-specific differences in Cell type
specific susceptibility to AZT and impact of resistance and in Table 3 for
AZT. For AZT, these cell-specific differences were attributed to
different contents of PPi and dTTP. (ii) Secondly, two different
outputs are measured by the two methods: In contrast to RT
activity, phenotypic assays measure the production of viral
proteins, which denotes a step in the viral life cycle following
polymerization and reverse transcription of the viral genome. (iii)
Thirdly, and most importantly, the IC50 values based on
enzymatic activity (as computed in this work) refer to intracellular
concentrations of AZT-triphosphate, while the fold change
derived by cell-based assays refers to the concentrations of
extracellular pro-drug (AZT) added to the medium surrounding
the cells. This has important consequences: AZT phosphorylation
is known to be non-linear and might be saturated at the
bottlenecking step of thymidilate kinase (monophosphate?
diphosphate) [53,54]. We have shown previously that the in vivo
maximally achievable AZT-TP concentration is close to the
clinically achieved AZT-TP concentration in peripheral blood
mononuclear cells (PBMCs), when 300 mg AZT is given twice
daily, see [53]. In order to disproportionately increase the
IC50(AZT) value several hundred-fold, as observed with some
mutants e.g. ‘M41L/D67N/K70R/T210W/Y215F’, at the enzy-
matic level all that is required is a minor fold change in the IC50
(for AZT-TP), that shifts the fifty percent inhibitory concentration
of intracellular AZT-TP beyond the maximally achievable levels.
Thus, by adding more extracellular AZT, sufficient concentrations
of AZT-TP may never be reached. In the case of saturating
intracellular AZT monophosphate (AZT-MP) concentrations, the
cell-specific levels of thymidilate kinase enzyme will ultimately
determine the maximally achievable AZT-TP concentration,
which are therefore also cell-specific [55].
In Table 4 we analyzed, based on the developed model, how
different mutations can specifically alter the efficacy of distinct
NRTIs and their combinations on DNA-directed polymerization
and at physiological concentrations. Estimated susceptibility
changes resulting from distinct mutations were qualitatively in good
agreement with results from cell culture assays (see [40]), although,
as mentioned earlier, it should be noted that a direct quantitative
comparison of our estimations with results from cell-culture assays
may not be possible. While estimating the effect of combinations of
NAs on DNA polymerization is straightforward using eq. (1)–(11),
we did not assess clinically relevant pharmacokinetic interactions
between different NAs. Pharmacokinetic interactions between
NRTIs of HIV-1 have mainly been attributed to interactions
during the cellular activation cascade [56]. For our estimations in
Table 4 we therefore assessed only drug combinations that use
distinct enzymes in their phosphorylation cascade and which
therefore bear lesser potential for pharmacokinetic interaction than
drugs which utilize the same intracellular phosphorylation pathway.
Inhibition of mitochondrial polymerase-c by NRTIs has been
proposed as a central process for their clinical toxicity [9]. We
therefore studied inhibition of polymerase-c by distinct NRTIs at
physiologically relevant triphosphate concentrations. The ranking
of polymerase-c inhibition by the analyzed NRTIs was in good
agreement with published results [9], indicating a strong inhibition
of pol{c by d4T and moderate inhibition by 3TC at
physiological intracellular triphosphate concentrations. However,
it should also be noted, that mitochondria in different tissues might
contain different levels of dNTP and NRTI-TPs and might
therefore be differentially prone to pol{c inhibition, potentially
contributing to site-specific toxicities of some NRTIs [9].
Mitochondrial toxicity of AZT has been explained by other
mechanisms than pol{c inhibition. In particular, AZT might
deplete dNTP pools in the mitochondria, rather than quasi-
terminate nascent mtDNA by its incorporation [57,58].
Although we demonstrated the use of the developed model on
nucleoside reverse transcriptase inhibitors of HIV-1 throughout
the article, we did not construct a mathematical model of the
complete reverse transcription process, but rather focussed on the
sub-process of polymerization, which is primarily targeted by
NRTIs and other NAs. The aim was to point out general
principles of inhibition and resistance development, rather than
establishing customized models for the respective targeted viral
processes. Therefore, the presented model can be used to also
assess effects on distinct polymerase enzymes, or as demonstrated
in Table 5 to assess off-target effects of NAs. Furthermore, the
model can readily be used to assess inhibition of polymerization by
NcRTIs, a novel class of pre-marketed nucleoside inhibitors which
compete with natural dNTPs for binding to the polymerase
enzyme, without becoming incorporated [59–61].
In the future, the developed model could be extended for the
‘‘dead-end complex’’-mechanism observed during inhibition of
HIV-1 RT [13], if respective kinetic parameters become available.
Extension of the model is straightforward, as it only requires the
introduction of an additional state in the mathematical model
(
*
i/? { in Fig. 1) and the subsequent derivation of the corresponding
equations, analogously to the derivations in this article.
Recent in vitro experiments with single-molecules of HIV-1 RT
indicated that additional complexities might occur during the
reverse transcription process, such as enzyme-template dissocia-
tion and association and reversal of orientation to perform distinct
tasks, such as RNAse H cleavage of the viral RNA template
[62,63]. While these results warrant further investigation, it has
been shown that in vivo an excess of RT (50–200 enzymes/virion)
in comparison to RNA template may be present [64], such that
different enzymes could perform different tasks (polymerization/
RNAse H) at the same time in vivo. The cooperativity of multiple
RT enzymes can also explain the distinct shape of the dose-
response curve observed in primary human cells with inhibitors
that directly target the enzyme, such as non-nucleoside reverse
transcriptase inhibitors (NNRTIs), in contrast to inhibitors that
target the RNA/DNA template (NRTIs) [65,66]. The develop-
ment of models of reverse transcription that also incorporate the
effects of non-nucleoside reverse transcriptase inhibitors (NNRTIs)
[67,68] warrants further mechanistic understanding of the
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complex overall process of reverse transcription and will be left for
future research. The developed model can however be readily be
used to model the effects of NAs and will be further extended to
model e.g. the complete reverse transcription process of HIV-1
genomic RNA, or analogous processes in other viruses (see also
supplementary Text S1).
Methods
Derivation of a recursive solution for the polymerization
times on arbitrary hetero-polymeric sequences
In this section we will derive the analytical solution for the
polymerization time given in eq. (10), which is based on ideas
given in [69]. Recall that the proposed model is a Markov jump
process and that the polymerization time T0?N is given by the
mean first passage time (MFPT) to go from state ‘0’ (initiation of
polymerization) to the state 0N 0 (final polymerization product).
Starting point for the derivation are the MFPT-equations
(i~0, . . . ,N{1) [70],
{1~{(rpol(iz1)zrpyro(i)zrterm(iz1))Ti?N
zrpol(iz1):Tiz1?Nzrpyro(i):Ti{1?Nzrterm(iz1):Tfiz1?N ,ð22Þ
{1~{rexc(iz1):Tfiz1?Nzrexc(iz1):Ti?N : ð23Þ
Eq. (23) yields
Tfiz1?N~ 1rexc(iz1)zTi?N
such that eq. (22) simplifies to
{1~{Ti?N (rpol(iz1)zrpyro(i)zrterm(iz1))zrpol(iz1):Tiz1?N
zrpyro(i):Ti{1?Nz
rterm(iz1)
rexc(iz1)
zrterm(iz1):Ti?N :
Further algebraic rearrangements yield
{1~{Ti?N (rpol(iz1)zrpyro(i))zrpol(iz1):Tiz1?N
zrpyro(i):Ti{1?Nz
rterm(iz1)
rexc(iz1)
,
and finally
Ti?N~
1
rpol(iz1)zrpyro(i)
1z
rterm(iz1)
rexc(iz1)
zrpol(iz1):Tiz1?Nzrpyro(i):Ti{1?N
 
:
ð24Þ
We define the general relation
Ti?iz1~Ti?N{Tiz1?N , ð25Þ
which allows us to expressT0?N as a telescope sum (TN?N~0), i.e.,
T0?N~
XN{1
i~0
Ti?iz1: ð26Þ
From the general relation (25), we can derive Tiz1?N~
Ti?N{Ti?iz1 and Ti{1?N~Ti?NzTi{1?i, which were substi-
tuted into equation (24). Rearrangement produces the recursion
Ti?iz1~
1
rpol(iz1)
1z
rterm(iz1)
rexc(iz1)
zrpyro(i):Ti{1?i
 
, ð27Þ
which equals
Ti?iz1~(tfiz1:ri?fiz1ztizri?i{1Ti{1?i) 1ri?iz1 , ð28Þ
with parameter definitions given in eq. (9) of the main text.
Equation (27) is satisfied by
Ti?iz1~
Xiz1
k~1
rterm(k)zrexc(k)
rpol(k):rexc(k)
P
i
j~k
rpyro(j)
rpol(jz1)
 
ð29Þ
such that the initial condition holds, i.e.,
T0?1~
1
rpol(1)
rterm(1)zrexc(1)
rexc(1)
 
:
Finally, inserting (29) into (26) results in the analytical expression
for T0?N ,
T0?N~
XN{1
i~0
Xiz1
k~1
rterm(k)zrexc(k)
rpol(k):rexc(k)
P
i
j~k
rpyro(j)
rpol(jz1)
 " #
: ð30Þ
Derivation of an analytic solution for polymerization
times of homo-polymeric sequences
In case where the sequence to be polymerized is homo-
polymeric, e.g. ‘Poly-A’, all rates are uniform, i.e., rpol(i):
rpol,rpyro(i):rpyro,rterm(i):rterm and rexc(i):rexc for any i. Then
by exploiting twice the identity
Xi
k~0
rpol
rpyro
 k
~
riz1pyro{r
iz1
pol
(rpyro{rpol):ripyro
ð31Þ
the polymerization time from eq. (30) simplifies to
T0?N~
rtermzrexc
rpol:rexc
 XN{1
i~0
rpyro
rpol
 iXi
k~0
rpol
rpyro
 k
~
rtermzrexc
rpol:rexc
 
1
rpol{rpyro
 XN{1
i~0
rpol{
rpyro
rpol
 i
rpyro
 !
~
rtermzrexc
rexc:(rpol{rpyro)
2
 !
rpyro
rpyro
rpol
 N
{N{1
 !
zrpol:N
 !
T0?N~
rtermzrexc
rexc
 
(rpolzrpyro)
N{1
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:(N{1)
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,
ð32Þ
which is displayed in eq. (16) of the main article.
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Determination of the fifty percent inhibitory
concentration (IC50)
Starting point for calculating the fifty percent inhibitory
concentration (for polymerization of uniform sequences) is
equation (19). We set
0:5~
rexc
rtermzrexc
: rpol
rpol(w)
u
2
rpol(w)
~
rtermzrexc
rexc:rpol
, ð33Þ
substitute eqs. (12)–(14) and solve for the NA concentration (that
yields 50% inhibition, the IC50 value). After rearranging, we get
the quadratic formula
a:IC50
2
zb:IC50zc:~0 ð34Þ
with
a~
KD,dNTP
KD,NA
(rexczkterm), b~kterm(KD,dNTPzdNTP)
c~{rexc
KD,NA
KD,dNTP
(KD,dNTPzdNTP)
2,
which yields
IC50~
rexc
ktermzrexc
KD,NA(KD,dNTPz½dNTP)
KD,dNTP
ð35Þ
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1Table S1. Pre-steady state kinetic constants for nucleoside incorporation by wild type HIV-1
reverse transcriptase
RNA-dependent DNA-dependent
KD µM kpol [s
−1] ref. KD µM kpol [s
−1] ref.
dATP 16 74 [1] 7.8 44.8 [1–3]
dTTP 25.5 87 [4, 5] 15.3 15.6 [2, 3, 5, 6]
dCTP 20 22.7 [3, 7–9] 18.25 10.2 [3, 7, 8, 10]
dGTP 11.5 34.5 [11, 12] 10 20 [11,12]
ddATP - - - 43.9 30.75 [1, 2]
3TC-TP - - - 20.17 0.038 [7, 10, 13]
TFV-DP - - - 40.5 28 [1, 13]
CBV-TP - - - 21 1 [14]
FTC-TP - - - 19 0.056 [10,15]
AZT-TP 22.8 54.3 [3–5] 7.15 1.9 [3, 5]
d4T-TP - - - 34.5 13.4 [6, 16]
Indicated parameters are average values from the respective literature sources.
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1Table S2. Fold change of kinetic parameters for DNA-dependent polymerization in various
HIV-1 reverse transcriptase mutants, relative to wildtype RT
M184V K65R K65R/M184V Q151M
KD kpol KD kpol KD kpol KD kpol ref.
dATP 2.4 0.66 0.93 0.23 4.9 0.4 2 1 [1–4]
dTTP 3.5 1.08 0.57 0.33 1.76 0.77 0.82 1.13 [1, 2, 4, 5]
dCTP 2.66 1.3 1.5 0.62 2.4 0.78 1.5 1.2 [1–4,6]
dGTP 1.75 1.5 1.65 0.37 4.7 1.1 0.52 1.1 [1, 7–10]
KD kterm KD kterm KD kterm KD kterm ref.
3TC-TP 35 0.55 0.77 0.081 17.9 0.035 0.23 0.32 [1, 6]
TFV-DP♭ 1.3 0.98 0.78 0.046 2.87 0.14 1.6 0.34 [1, 3]
CBV-TP§ 2.43 0.45 - - - - 0.07 0.11 [8]
FTC-TP - - 1.59 0.128 1 0.016 0.32 0.42 [6]
ddATP - - 1.4 0.11 - - - - [1, 2]
AZT-TP - - - - - - - - -
D4T-TP‡ 12.6 1.86 - - - - - - [5]
rexc(wt) was set to the value of 0.0016 [1/s] in resting CD4
+ T-cells for thymidine- and
adenosine analogs respectively, see Table S3 (supplementary material) and eq. (18) (main
article) and to the value of 0.00053 [1/s] for guanine- and cytosine analogs, see [8]. ♭
excision of TFV-TP from terminated templates was assumed to be 100%, 50%, 100% and
40% of the wild type excision rate for the M184V, the K65R, the Q151M and the
K65R/M184V mutant, see [11]. § CBV-TP excision in the Q151M mutant was set to
5300% of wild type excision, see [8]. D4T-TP excision in the M184V mutant was set to
83% of the wild type excision, assuming a similar effect of M184V on D4T-TP and
AZT-TP [11]. If no other information was available, excisions of nucleoside analogs in the
mutant enzymes were assumed to be equal to the wild type excision rate.
2Table S2. (continued)
Q151Mc∗ Q151Mc/K70Q 4-TAM∗∗ 4-TAM(RNA)
KD kpol KD kpol KD kpol KD kpol ref.
dATP 3.7 2.41 1.92 2.3 1† 1† 1† 1† [4, 12]
dTTP 0.57 0.58 0.57‡ 0.58‡ 0.53 0.24 1.6 0.72 [4, 13]
dCTP 0.82 1.1 0.82‡ 1.1‡ 1† 1† 1† 1† [4]
dGTP 4.1 3.8 4.1‡ 3.8‡ 0.79 1.15 2.83 1.8 [7, 10]
KD kterm KD kterm KD kterm KD kterm ref.
3TC-TP - - - - - - - - -
TFV-DP 2.3 0.46 4.7 0.36 - - - - [12]
CBV-TP - - - - - - - - -
FTC-TP - - - - - - - - -
ddATP - - - - - - - - -
AZT-TP - - - - 3.5 2.57 2.46 0.67 [13]
D4T-TP - - - - - - - - -
∗ Q151Mc denotes the ’A62V/V75I/F77L/F116Y/Q151M’ mutant. ∗∗ 4-TAM denotes the
’D67N/K70R/T215Y/K219Q’ mutant. † set to the value of 1, because of insufficient
information. ‡ set equal to the rate in Q151Mc.
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1Table S3. Pre-steady state kinetic constants for AZT excision by HIV-1 reverse
transcriptase wildtype and ’D67N/K70R/T215Y/K219Q’ mutant
wild type ’D67N/K70R/T215Y/K219Q’
DNA RNA ref DNA RNA ref
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1S1 Inhibition of Polymerization and Probability to Suc-
cessfully Complete Reverse Transcription of HIV-1
The model presented in the main manuscript is built around the concept of time required
for completion of the polymerization reaction. In particular, we derived a parameter (1−ε),
which denotes the residual polymerization in the presence of NAs. Here, we want to give
an example of how inhibition of the polymerization reaction could alter the probability to
successfully complete reverse transcription ρRT. The example will be based on HIV-1. For
this particular virus the targeted process is reverse transcription, which takes place after
the virus penetrated the target cell, but before it is stably integrated into the host cell’s
DNA [1], see also Fig. S1. If we assume that the decay kinetics of the HIV-RT complex is
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Figure S1. Reverse transcrition/polymerization during the life-cycle of HIV. The two
competing processes of reverse transcription kRT and the inactivation of the RT complex δRT are
highlighted. Only if HIV succeeds to finalize RT, before its inactivation, subsequent steps of host cell
infection can occur.
linear, then the probability to successfully finalize RT in the absence of treatment is given
by
ρφ,RT =
kφ,RT
kφ,RT + δRT
, (1)
where kφ,RT and δRT denote the rate of reverse transcription in the absence of drugs φ and
the rate of decay of the RT complex [1/time]. Estimated values of ρφ,RT range from 0.15 [2]
to 0.5 [3] in unstimulated CD4+ T-cells. Further, we assume that kφ,RT ≈ kφ,Pol, namely
that the sub-process of polymerization requires most time during reverse transcription in
the absence of inhibitors (strand transfer, initiation and RNAse H, either occur in parallel
or require a much smaller fraction of time compared to polymerization) [4]. Therefore, in
2the presence of inhibitors we will also have kNA,RT ≈ kNA,Pol, because NAs prolong the time
required to finalize polymerization, i.e reduce kPol. It follows, that
ρNA,RT =
kNA,RT
kNA,RT+δRT
(probability to finish RT in the presence of NAs), (2)
i.e. NAs decrease the probability that HIV can successfully finalize RT by decreasing kRT.
Therefore, NAs indirectly contribute to the clearance of HIV’s RT-complex by intracellular
inactivation processes. Using kNA,Pol ≈ (1 − ε) · kφ,Pol and kφ,RT ≈ kφ,Pol, we can finally
set kNA,RT ≈ (1 − ε) · kφ,RT , where (1 − ε) denotes the residual polymerization, defined
in eqs. (1-2) of the main article. After some rearrangement, we derive the relation of the
residual probability to finalize RT
ρNA,RT
ρφ,RT
and residual polymerization (1− ε):
ρNA,RT ≈
ρφ,RT
ρφ,RT+
1−ρφ,RT
(1−ε)
(3)
⇒
ρNA,RT
ρφ,RT
≈
1
ρφ,RT+
1−ρφ,RT
(1−ε)
(residual probability to finish RT), (4)
which is shown in Fig. S2 (left panel). In summary, it is possible to compute the residual
probability to finalize RT
ρNA,RT
ρφ,RT
in the presence of NAs from the residual polymerization
(1− ε). This conversion does not affect the shape of the dose-response curve (Fig. S2, right
panel), but results in a shift of the dose-response curve towards higher NA concentrations,
i.e. polymerization is more strongly inhibited than the probability to finalize RT. The extend
of the shift depends on the probability to finalize RT in the absence of inhibitors ρφ,RT. If RT
is usually finalized in the absence of drugs, there will be a greater shift of the dose-response
curve towards the right, i.e. the virus is less sensitive to treatment. Given the derivations
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Figure S2. Relation of the residual probability to finalize RT and residual polymerization.
Left: Relation of the residual probability to finalize RT
ρNA,RT
ρφ,RT
and residual polymerization (1− ε) if the
probability to finalize RT in the absence of inhibitors was ρφ,RT = 15% (dashed red line), or ρφ,RT = 50%
(solid green line). Right: Comparison of the dose-response curve with regard to residual RNA-dependent
polymerization in the presence of AZT-TP in resting CD4+ T-cells (solid blue line) and the residual
probability to finalize RT, if the probability to finalize RT in the absence of inhibitors was ρφ,RT = 15%
(dashed red line), or ρφ,RT = 50% (solid green line).
and assumptions above, it is also possible to fully mechanistically model the effects of NAs
(e.g. NRTIs), on the viral life cycle and virus load, using the equations provided in von
Kleist et al. [1] (see eqs. (7)-(8) and supplementary eqs. (S21-S26) therein).
3The equations above (in particular eq. (4)) also hold for other viruses, in which the
processes of polymerization and inactivation are competing.
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